Please use this identifier to cite or link to this item:
Title: Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women
Author: Grover-Paez, F.
Zavalza-Gomez, A.B.
Anaya-Prado, R.
Issue Date: 2013
Abstract: Objective: To investigate the effects of raloxifene on the insulin sensitivity and lipid profile in insulin-sensitive and insulin-resistant postmenopausal women. Study design: This placebo-controlled, double-blind, randomized study involved 64 postmenopausal women aged between 45 and 55 years. All subjects were screened with the insulin resistance homeostasis model assessment (IR-HOMA) and those patients in the lowest quartile (n = 16) were assigned as insulin sensitive and those in the highest quartile as insulin resistant (n = 16). Patients in both groups received either raloxifene hydrochloride (60 mg/day) or a placebo for a period of 12 weeks. Insulin sensitivity, the serum lipid profile and anthropometric measurements were established before and after therapy. Results: Women with the highest IR-HOMA scores were associated with a significantly higher weight, body mass index, waist and waist-to-hip ratio (p < 0.05). Raloxifene significantly reduced the IR-HOMA scores from 5.76 ± 2.91 to 1.93 ± 0.96 (p = 0.02) and modified the lipid profile in insulin-resistant patients when compared with the placebo group and those patients receiving raloxifene in the insulin-sensitive group. Conclusion: Raloxifene reduced insulin resistance and modified the lipid profile in insulin-resistant postmenopausal women. © 2013 Informa UK Ltd.
Appears in Collections:Producción científica UdeG (prueba)

Files in This Item:
There are no files associated with this item.

Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.